Edgewise Therapeutics Issues Inducement Grants Under Nasdaq Regulations Edgewise Therapeutics announced the grant of stock options to new employees to incentivize their joining, in line with Nasdaq regulations.

Edgewise Therapeutics Issues Inducement Grants Under Nasdaq Regulations #USA #biopharmaceuticals #Boulder #muscle_diseases #Edgewise_Therapeutics

Edgewise Therapeutics to Showcase Innovations at 2026 Biotech Summit Edgewise Therapeutics, a leader in muscle disease therapies, will present key findings at the Guggenheim Emerging Outlook Biotech Summit on February 12, 2026.

Edgewise Therapeutics to Showcase Innovations at 2026 Biotech Summit #United_States #biotechnology #Boulder #muscle_diseases #Edgewise_Therapeutics

Edgewise Therapeutics Outlines Strategic Priorities and Updates for 2026 In an important update, Edgewise Therapeutics outlines its strategic milestones for 2026, highlighting advancements in therapies for muscle diseases and cardiac conditions.

Edgewise Therapeutics Outlines Strategic Priorities and Updates for 2026 #United_States #Boulder #muscle_diseases #Edgewise_Therapeutics #cardiac_therapies

Edgewise Therapeutics Announces Participation in Noteworthy Investor Conferences Edgewise Therapeutics, a biopharmaceutical leader, will be featured in prominent investor conferences showcasing innovative therapies for muscle diseases.

Edgewise Therapeutics Announces Participation in Noteworthy Investor Conferences #United_States #Boulder #muscle_diseases #Edgewise_Therapeutics #EWTX

Avidity Biosciences' Plans to Submit First BLA by 2025 for Rare Muscle Diseases Avidity Biosciences is gearing up for a transformative 2025 with its first Biologics License Application submission, marking a major step in rare muscle disease treatment.

Avidity Biosciences' Plans to Submit First BLA by 2025 for Rare Muscle Diseases #United_States #San_Diego #RNA_Therapeutics #Avidity_Biosciences #muscle_diseases